A lesser known cannabis component known as CBG could represent a novel treatment in the treatment of rheumatoid arthritis (RA), according to a new study.
Researchers at the Rambam Health Care Campus in Israel released preclinical findings from a study examining cannabigerol, a non-intoxicating cannabinoid, and its potential to reduce inflammation associated with arthritis.
While most conventional RA therapies target certain proteins called cytokines, the study authors described using CBG to directly regulate white blood cells, or neutrophils, that can release certain cytokines linked to inflammation. The research findings were recently published in the journal Pharmaceuticals.
The preclinical study involved introducing CBG to isolated neutrophils extracted human blood cells, as well as administering the cannabis compound to lab mice. Researchers determined that “CBG has anti-inflammatory capacity and therapeutic potential in regulating neutrophil-mediated immunity in RA.”
“To date, there is no treatment that specifically targets neutrophils,” the study authors wrote. Yet they found that “CBG reduces the inflammatory output of human neutrophils by suppressing TNF-α and IL-6 production,” referring to select cytokines.
“These findings highlight CBG as an effective preclinical modulator candidate for affecting neutrophil-mediated immune responses and attenuating inflammation in rheumatoid arthritis.”
Specifically, cannabigerol was associated with deceases in the
Read full article on Marijuana Moment
